Abstract
Oral candidiasis treatment in neonates and infants is still a current issue. Until recently, the therapeutic solution of this disease has been consisting mainly in using extemporaneously prepared medicinal products in the oromucosal cavity containing non-specific antifungal agents.
Although oromucosal gels and suspensions containing specific antifungal agents are not available as registered products in the Czech Republic, during the past five years got to enrichment of the portfolio for compounding with new substances. Nystatin and miconazole are newly available for compounding and even they can be successfully used for the treatment of oromucosal candidiasis in neonates, infants, children and adults.
The paper aim is to inform physicians of treatment possibilities, oromucosal candidiasis compounded preparations. The paper provides an overview of the available products.
It focuses on the new substances - nystatin and miconazole - and presents the current magistral formulas that can be used for the treatment of oromucosal candidiasis (thrush) and that could thus completely replace the widely prescribed preparations with gentian (methyl) violet. Presented formulas were created by the authors, who also checked in practice, the active substance for the extemporaneous preparation are currently available for routine prescription and yet fully covered by public health insurance.